Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity
A Phase I Trial
Darryl P. Leong, Tammy Cosman, Muhammad M. Alhussein, Nidhi Kumar Tyagi, Sarah Karampatos, Carly C. Barron, Douglas Wright, Vikas Tandon, Patrick Magloire, Philip Joseph, David Conen, P.J. Devereaux, Peter M. Ellis, Som D. Mukherjee and Sukhbinder Dhesy-Thind
Continuing Trastuzumab Despite Mild Cardiotoxicity: LVEF Over Time
(A) Left ventricular ejection fraction (LVEF) progressively increased despite ongoing trastuzumab in individuals with mild trastuzumab cardiotoxicity when trastuzumab was accompanied by the administration of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and/or a beta-blocker. #p < 0.001 as compared with the enrollment left ventricular ejection fraction indicating significant improvement in left ventricular ejection fraction as compared with the left ventricular ejection fraction at enrollment. (B) Left ventricular ejection fraction while continuing trastuzumab and after completion of trastuzumab. *p = 0.53 compared with left ventricular ejection fraction at enrollment; #p = 0.025 compared with left ventricular ejection fraction at enrollment.